lete-cel (Letetresgene Autoleucel, GSK3377794)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for lete-cel (Letetresgene Autoleucel, GSK3377794), covering 2023-08-07 to 2023-08-07. Get the full timeline:
Most recent: Clinical Trial Update: Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab [Phase 1, Phase 2]